November 7, 2023

The Listing Department Dept. of Listing Operations

National Stock Exchange of India Limited BSE Limited,
Exchange Plaza, 5th Floor, Plot No. C/1 P J Towers, Dalal Street,
G Block, Bandra-Kurla Complex, Bandra (E) Mumbai -400001, India
Mumbai – 400 051

Symbol: YATHARTH Scrip Code: 543950

Dear Sir/Ma’am,

Sub:-Investor's presentation- Q2 &FY24 Results.

Please find enclosed Investor's Presentation for Q2 & FY24 Results pursuant to Regulation 30 of
the SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015.

Kindly take the same in your records.

Thanking you,

Your faithfully,
For Yatharth Hospital and Trauma Care Services Limited

Ritesh Mishra
Company Secretary & Compliance Officer
Enclosed: As above
www.yatharthhospitals.com

Q2 & H1 FY24
Earnings Presentation
November 7, 2023
1
 Disclaimer
Certain matters discussed in this Presentation may contain statements regarding the company’s market
opportunity and business prospects that are individually and collectively forward-looking statements. Such
forward-looking statements doesn’t guarantee future performance and are subject to known and unknown
risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but
are not limited to, the performance of the economy, industry, competition, the company’s ability to
successfully implement its strategy, technological implementation, changes and advancements, the
company’s market preferences and its exposure to market risks, as well as other risks. The company’s actual
results, levels of activity, performance or achievements could differ materially and adversely from results
expressed in or implied by this presentation. The company assumes no obligation to update any forward-
looking information contained in this presentation. Any forward-looking statements and projections made
by third parties included in this presentation are not adopted by the company and the company is not
responsible for such third-party statements and projections. You are cautioned not to place undue reliance
on these forward-looking statements, which are based on the current view of the management of the
Company on future events.

2
 Q2 & H1 FY24
Performance
Highlights

3
 Q2 & H1 FY24 Financial Highlights
Q2 H1
Rs. 1,713 mn
+34% YoY
Rs. 3,258 mn
+11% QoQ +36% YoY
Revenue

Margin Rs. 456 mn Margin

Rs. 870 mn
26.6% +36% YoY
+47% YoY 26.7%
+40bps YoY +10% QoQ EBITDA +192bps YoY

Margin Rs. 276 mn Margin

Rs. 466 mn 14.3%
16.1% +70% YoY
+71% YoY
+345bps YoY +45% QoQ PAT +293bps YoY

Net Cash RoCE RoE

Rs. 3,109 mn 25% 19%
Capital

➢ Yatharth Hospitals turns net debt-free during the quarter

➢ Finance cost reduces by 42% YoY and 50% QoQ to Rs. 29 mn during the quarter. Full Impact of debt reduction on
4 finance cost to be further visible during Q3
 Financial Highlights
Revenue (Rs mn) EBITDA (Rs mn) & EBITDA%
+34% +36%

26.8% 26.7%

3,258
26.2% 26.6%
1000 27%
99 5
99 0
1000 27% 98 5
99 5 98 0

24.8%
99 0 975

+11%
98 5 970
98 0 96 5 26%
975 96 0
970 95 5
96 5 26% 95 0
96 0 94 5
95 5 94 0
95 0 935
94 5 930
94 0 925 25%
935 920
930 915
925 25% 910
920 90 5
915 90 0
910 89 5
90 5 89 0 24%
90 0 88 5
89 5 88 0
89 0 24% 875
88 5 870
88 0 86 5
875 86 0
870 85 5
86 5 85 0 23%
86 0 84 5
85 5 23% 84 0
85 0 835
84 5 830
84 0 825
835 820
830 815 22%
825 810
820 80 5
815 22% 80 0
810 795
80 5 790
80 0 785
795 780 21%
790 775
785 770
780 21% 765
775 760
770

1,713
765 755
760 750
755 745

2,390
750 740 20%
745 735
740 20% 730
735 725
730 720
725 715
720 710
715 705 19%
710 700
705 19% 69 5
700 69 0
69 5 68 5
69 0 68 0
1,545
68 5 675
68 0 670 18%
675 66 5
670 66 0
66 5 18% 65 5
66 0 65 0
65 5 64 5
65 0 64 0
64 5 635
64 0 630 17%
635 625
630 17% 620
625 615
620 610
615 60 5
610 60 0
60 5 59 5 16%
60 0 59 0
59 5 16% 58 5
59 0 58 0
58 5 575
58 0 570
575 56 5
570 56 0
56 5 55 5 15%
1,279

56 0 55 0
55 5 15% 54 5
55 0 54 0
54 5 535
54 0 530
535 525
530 520

870
515 14%
525
520 14% 510
515 50 5
510 50 0
50 5 49 5
50 0 49 0
49 5 48 5 13%
49 0 48 0
48 5 475
48 0 13% 470
475 46 5
470 46 0
46 5 45 5
46 0 45 0
45 5 44 5 12%
45 0 44 0
44 5 12% 435
44 0 430
435 425
430 420
425 415
420 410 11%
415 40 5
410 11% 40 0
40 5 395
40 0 390
395 385
390 380

592
385 375
380 370 10%
375 365
370 10% 360
365 355
360 350
355 345
350 340
345 335 9%
340 330
335 9% 325
330 320
325 315
320

456
315 310
310 305
305 300 8%
300 295
295 8% 290
290 285
280

414
285 275
280 270
275 265
270 260 7%
265 255
260 7% 250
255

335
250 245
245 240
240 235
235 230
230 225 6%
225 220
220 6% 215
215 210
210 205
205 200
200 195
195 190
190 185 5%
185 5% 180
180 175
175 170
170 165
165 160
160 155
155 150 4%
150 145
145 4% 140
140 135
135 130
130 125
125 120
120 115
115 110 3%
110 3% 105
105 100
100 95
95 90
90 85
85 80
80 75 2%
75 2% 70
70 65
65 60
60 55
55 50
50 45
45 40 1%
40 35
35 1% 30
30 25
25 20
20 15
15 10
10 5
5 0 0%
0 0%

Q2FY23 Q1FY24 Q2FY24 H1FY23 H1FY24 Q2FY23 Q1FY24 Q2FY24 H1FY23 H1FY24
1000 27%
99 5
99 0
98 5
98 0
975
1000 27% 970
99 5 96 5 26%
99 0 96 0
98 5 95 5
98 0 95 0

PAT (Rs mn) & PAT%

975 94 5

Finance Cost (Rs mn)

970 94 0
96 5 26% 935
96 0 930
95 5 925 25%
95 0 920
94 5 915
94 0 910
935 90 5
930 90 0
925 25% 89 5
920 89 0 24%
915 88 5
910 88 0
90 5 875
90 0 870
89 5 86 5
89 0 24% 86 0
88 5 85 5
88 0 85 0 23%
875
870 84 5
86 5 84 0
86 0 835
85 5 830
85 0 23% 825
84 5 820
84 0 815 22%
835 810
830 80 5
825 80 0
820 795
815 22% 790
810 785
80 5 780 21%
80 0 775
795 770
790 765
785 760
780 21% 755
775 750
770 745
765 740 20%
760 735
755 730
750 725
745 720
740 20% 715
735 710
730 705
725 19%
700
720 69 5
715 69 0
710 68 5
95
705 19% 68 0
700 675
69 5
69 0 670
66 5 18%
68 5
68 0 66 0
675 65 5
670 65 0
66 5 18% 64 5
66 0 64 0
65 5 635
65 0 630 17%
64 5 625

14.3%
64 0 620
615

16.1%
635
630 17% 610
625 60 5
620 60 0
615 59 5 16%
610 59 0
60 5 58 5

89
60 0 58 0
59 5 16% 575
59 0 570
58 5 56 5
58 0 56 0
575 55 5 15%
570 55 0
56 5 54 5
56 0 54 0
55 5 15% 535
55 0 530
54 5 525
54 0 520
535 14%
515
530 510
525 50 5
520 14% 50 0
515 49 5
510

12.7%
50 5 49 0
48 5
59

50 0 13%
48 0

12.3%
49 5
49 0 475
48 5 470
48 0 13% 46 5
46 0

11.4%
475
470 45 5
46 5 45 0
46 0 44 5 12%
45 5 44 0
45 0 435
44 5 12% 430
44 0 425
435 420
430 415
425 410
420 40 5 11%
415
50

40 0
410 11% 395
40 5 390
40 0 385
395 380
390 375
385 370 10%
380 365
375 360
370 10% 355
365 350
360 345
355 340
350 335
345 9%
340 330
335 325
9% 320
330
325 315
320 310
315 305
310 300
295 8%
305

466
300 290
295 8% 285
290 280
285 275
280 270
275 265
270 260 7%
265 255
260 7% 250
255 245
250 240
245 235
240 230
235 225
230 220 6%
29

225 215
220 6%
210
215 205
210 200

272
205 195
200 190
195 185 5%

276
190 180
185 5% 175
180 170
175 165
170 160
165 155
160 150
155 4%
150 145
4% 140

190
145
140 135
135 130
130 125

162
125 120
120 115
115 110 3%
110 3% 105
105 100
100 95
95 90
90 85
85 80
80 75 2%
75 2% 70
70 65
65 60
60 55
55 50
50 45
45 40
40 35 1%
35 1%
30
30 25
25 20
20 15
15 10
10 5
5 0 0%
0 0%

Q2FY23 Q1FY24 Q2FY24 H1FY23 H1FY24 Q2FY23 Q1FY24 Q2FY24 H1FY23 H1FY24
5
 Strengthened Balance Sheet
Equity Base Expansion (Rs mn)
40% Debt Repayment – 2,450 mn
8,065

Organic Capex – 1,326 mn

22%
Rs 6,100 mn
IPO Proceeds
11% 1,830
Inorganic Expansion – 650 mn
27%
General Corporate & Issue
Mar-23 Sep-23
Exps. – 1,674 mn

Debt Repayment (Rs mn)

2,674

Ongoing Capex (Rs mn)

Capex Incurred
Particulars
till Sep 30, 2023
Machinery & Equipment purchase
58 mn
at all hospitals
132

Mar-23 Sep-23
6
 Operational Highlights
❑ Occupancy increases to 57% in Q2FY24, vs 45% in Q2FY23 and 50% in Q1FY24; Noida and Greater Noida hospital reported

highest occupancy levels of 96% and 73% respectively during the quarter

❑ Inpatient revenue up by 37% YoY during the quarter, and 40% YoY during the half-year period

❑ ARPOB is Rs. 27,833 in H1 FY24, up by 6% YoY; Noida extension hospital reported highest ARPOB of Rs. 33,181 in H1 FY24

❑ Nephrology & urology and neurosciences grew 40%+, while Gastroenterology, Pulmonology and Oncology grew over 2x on a

YoY basis; Radiation oncology line has arrived at Noida extension, and is expected to start operations in Jan-24, offering full

spectrum of oncology treatment, while robotic surgeries is expected to start operations in the coming quarter

❑ The Income Tax Department conducted a search operation at the Company premises from October 19 th to 22nd, 2023 and did

not find any preliminary unaccounted cash or incriminating evidences during the said operation. The company is duly

replying to the queries of the tax authorities and does not foresee any impact on the operating and financial performance of

the company

7
 Operational KPIs

IPD & OPD Revenue (Rs mn) IPD & OPD Volumes (in ‘000s)
IPD Revenue OPD Revenue IPD Volume OPD Volume
3,258
188 185
1,713 2,389 410 101
1,545 97
89
1,279 224 352
186
192 166 161
2,848 89 84
1,489 77
1,359 2,037
1,087
12 12 13 22 24

Q2FY23 Q1FY24 Q2FY24 H1FY23 H1FY24 Q2FY23 Q1FY24 Q2FY24 H1FY23 H1FY24

Revenue Mix – H1FY24 (%) ALOS (days)

5%
4.95 4.79
Greater Noida
36% Noida Extension 4.63
29%
Noida 4.12
4.22
Jhansi-Orchha

30% Q2FY23 Q1FY24 Q2FY24 H1FY23 H1FY24

8
ALOS – Average Length of Stay
 Operational KPIs
3,258
Revenue (Rs mn)

2,389

1,545 1,713
1,279 1,172
949 825 953 971
497 444 559 465 443 613 488 529 585
317 162
21 79 83 30

Q2FY23 Q1FY24 Q2FY24 H1FY23 H1FY24

ARPOB (Rs)

33,926

33,181
32,581
31,136

30,394
28,140

27,833
27,561

26,302
26,168

25,799

25,691
25,589
24,648

24,605
20,232

18,864
18,265

18,225
17,726
25,439

27,664

27,830
26,061
28,014

Q2FY23 Q1FY24 Q2FY24 H1FY23 H1FY24

96% 94%
Occupancy (%)

91% 92%
85%
73% 70%
64% 66%
57% 60% 54%
45% 50%
37%
45% 42% 41%
28% 27%
17% 20% 19%
5% 4%

Q2FY23 Q1FY24 Q2FY24 H1FY23 H1FY24

9
Greater Noida Noida Noida Extension Jhansi-Orchha Consolidated
 Our Specialties
Diversified specialty services

H1 FY24 Mix (%)

2023 31% 10% 10% 9% 9% 6% 5% 5% 4% 3% 9%

Cardiology
10%

Internal
Nephrology &
Medicine 2022 50%
urology, 10%
33%

Neurosciences
9%
Oncology, 3%
2021 56%
Gynecology, 4% General surgery,
7%
Gastroenterology, 4%
Others*, 6% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Pediatrics, 4%
Pulmonology
Internal Medicine Neurosciences
Orthopedics & 5%
Cardiology Nephology & Urology
spine & General Surgery Orthopedics, Spine & Rehumatology
rheumatology Pediatrics Pulmonology
5% Gynecology Gastroenterology
Others

10
 Clinical Achievements

11
 Profit & Loss Summary
Change Change Change
Particulars (Rs Mn) Q2FY24 Q2FY23 Q1FY24 H1FY24 H1FY23
YoY QoQ YoY
Revenue from Operations 1,713 1,279 34% 1,545 11% 3,258 2,390 36%
Medical Consumables &
360 231 56% 281 28% 641 444 44%
Pharmacy items
Employee Expenses 284 237 20% 268 6% 552 433 27%

Other Expenses 613 475 29% 582 5% 1,195 921 30%

EBITDA 456 335 36% 414 10% 870 592 47%

EBITDA Margin % 26.6% 26.2% 40 bps 26.8% (20 bps) 26.7% 24.8% 192 bps

Depreciation and amortisation 69 63 10% 69 0% 138 123 12%

Financial Cost 29 50 (42%) 59 (51%) 89 95 (6%)

Other Income 38 7 443% 8 375% 46 13 254%

Profit Before Tax (PBT) 396 230 72% 294 35% 689 387 78%

Tax 120 68 76% 103 17% 223 115 94%

Profit After Tax (PAT) 276 162 70% 190 45% 466 272 71%

PAT Margin % 16.1% 12.7% 345 bps 12.3% 380 bps 14.3% 11.4% 293 bps

12
 Balance Sheet

Particulars (Rs Mn) Sep-23 Mar-23 Particulars (Rs Mn) Sep-23 Mar-23

Shareholders Equity 8,065 1,830 Fixed Assets (including Goodwill) 2,925 2,950

Borrowings 105 2,638 Right to Use Assets 25 35

Lease Liabilities 26 36 Financial Assets 16 20

Trade Payables 146 169 Inventories 59 61

Other financial liabilities 162 142 Trade Receivables 1,741 1,076

Other liabilities and provisions 38 45 Cash & Bank Balances 3,240 384

Total Liabilities 8,542 4,860 Other assets 535 333

Total Assets 8,542 4,860

13
 About The
Company

14
 At a Glance
Leading super specialty hospital in Delhi-NCR

Among top 10 largest private hospitals One-stop destination for patient needs providing all
of Delhi NCR region in terms of number levels of healthcare services from primary to tertiary
of beds

2019
Noida Extension
4 10 1,405
Hospitals Center of Excellence Operational Beds
2013
Noida

2010
Greater Noida
Rs. 27,833 4.79 days
ARPOB* ALOS*

2022 Revenue EBITDA PAT RoCE

Jhansi-Orchha

Rs 1,338mn Rs 658mn
FY23 Rs 5,203mn 26.1%
Margin 25.7% Margin 12.6%
FY21-23 CAGR +51%
FY21-23 CAGR +41% FY21-23 CAGR +90%
H1 FY24

Rs 3,258mn Rs 870mn Rs 466mn

Margin 26.7% Margin 14.3% 24.5%
+36% YoY
15 +290bps YoY
+190bps YoY
*H1FY24 figures
 Our Journey
Growing presence across regions and services

2008 2013 2019 2023

Incorporation of Established our Commencement of Listing on NSE & BSE
company and second 250 bedded our third hospital,
commencement of hospital, in Noida Noida Extension
operations hospital, in May 2019,
pursuant to the
acquisition of
subsidiary AKS in 2016

Acquisition of 4th
Expansion of our hospital - Jhansi
first hospital, Orchha hospital
Established our first Greater Noida adding 305 beds,
hospital in Greater hospital, to 400 pursuant to acquisition
Noida beds of subsidiary, Ramraja

2010 2018 2022

Continued expansion into specialized services - Neurology, Cardiology, Nephrology, Orthopedics and Oncology

Plan to introduce radiation therapy and liver transplant operations

16
 Greater Noida Hospital Overview
Revenue from Operations (Rs mn) Provides a wide spectrum of super specialty services in the field of
1,994 cardiology, cardiovascular and thoracic surgery, neurology, neurosurgery,
1,702
urology, nephrology, oncology, gastroenterology etc.
1,172
949 Strategy to develop this hospital as the Centre of Excellence for Human
811
Organ Transplant and as a major center for medical tourism

Company has acquired land parcel of 1,885 sq mt adjacent to hospital,

FY21 FY22 FY23 H1FY23 H1FY24
aimed towards expansion of bed capacity to 600 from 400 presently
In-Patient and Out-Patient Volume

137,937
116,300
82,520
69,328 69,269 2010 Incorporated
9,322 15,020 17,255 8,634 8,726

FY21 FY22 FY23 H1FY23 H1FY24

400 Bed Capacity
In-Patient Volume Out-Patient Volume

ARPOB (Rs) ALOS (days)

112 ICU
27,830
26,539

4.8 4.8
23,621

4.4
21,754

4.0

70% Occupancy
17 FY21 FY22 FY23 H1FY24 FY21 FY22 FY23 H1FY24
Note: H1FY24 figures
 Noida Hospital Overview
Revenue from Operations (Rs mn) Provides services across 30 specialties, including cardiac sciences,
1,721
orthopedics, nephrology, urology, neurosciences, gastroenterology, etc.
1,283
953
825 Strategy to improve ALOS and improve the combination of super
681
specialties, for better ARPOB

FY21 FY22 FY23 H1FY23 H1FY24

In-Patient and Out-Patient Volume

72,906
56,799
2013 Incorporated
44,671
35,858 36,821

7,816 9,316 11,957 6,073 6,248

FY21 FY22
In-Patient Volume
FY23 H1FY23
Out-Patient Volume
H1FY24
250 Bed Capacity
ARPOB (Rs) ALOS (days)

81 ICU
25,691
24,949

6.1 5.8 5.9

22,617

94% Occupancy
21,436

4.1

18 FY21 FY22 FY23 H1FY24 FY21 FY22 FY23 H1FY24

Note: H1FY24 figures
 Noida Extension Hospital Overview
Revenue from Operations (Rs mn) Plan to develop this hospital as a Centre of Excellence for oncology
treatment and robotic surgeries
1,357
1,023 971 Plan to start liver transplant operations; recently started bone marrow and
795
585 kidney transplant operations. Radiation oncology line expected to be
commissioned by Jan-24, offering full spectrum of oncology treatments

Company is declared as highest bidder for an adjacent land, which will

FY21 FY22 FY23 H1FY23 H1FY24
support future bed capacity expansion
In-Patient and Out-Patient Volume

102,278

49,730 52,893 46,258

2019 Incorporated
8,564
4,218 8,457 14,186 6,862 7,646

FY21 FY22
In-Patient Volume
FY23 H1FY23
Out-Patient Volume
H1FY24 450 Bed Capacity
ARPOB (Rs) ALOS (days)

125 ICU
33,181
30,475

9.1
24,534
20,710

4.9
3.1 3.8 41% Occupancy
19 FY21 FY22 FY23 H1FY24 FY21 FY22 FY23 H1FY24
Note: H1FY24 figures
 Jhansi – Orchha Hospital Overview
Revenue from Operations (Rs mn) One of the largest hospital in Jhansi-Orchha-Gwalior region, has
162 infrastructure to operate all the major super specialties
131

Acquired in FY22, aimed at further expanding into new geographies and

growing presence in the regional healthcare market
30

FY23 H1FY23 H1FY24

Plan to introduce a fully functional oncology treatment unit in FY2025

In-Patient and Out-Patient Volume

16,639

7,785 8,548
2022 Incorporated
1,960 1,800
462

FY23 H1FY23
In-Patient Volume Out-Patient Volume
H1FY24
305 Bed Capacity
ARPOB (Rs) ALOS (days)

4.8
76 ICU
18,864

3.8

19% Occupancy
17,692

20 FY23 H1FY24 FY23 H1FY24

Note: H1FY24 figures
 Our Specialties
Expanding share of high value specialties

Revenue change - FY23 vs FY21

30 Specialties and FY21-23

CAGR
13% 66% 77% 72% 82% 65% 79% 108% 131% 209% 53%

Super specialties
including 10 Centers of
FY2021 FY2023

Excellence (COE)

Revenue (Rs. mn)

Our COEs
➢ Centre of Internal Medicine

1,637

442
509

509

265
295

230

242
473

158

147
➢ Centre of Cardiology
➢ Centre of Neurosciences

Medicine

Pulmonology

Others
Rehumatology
Neurosciences

General Surgery

Nephology &

Gynecology
Cardiology

Gastroenterology
Pediatrics
Centre of General surgery Internal

Orthopedics,
➢

Urology
➢ Centre of Nephrology & Urology

Spine &
➢ Centre of Pediatrics
➢ Centre of Gastroenterology
➢ Centre of Pulmonology
➢ Centre of Gynecology ▪ Increase in share of higher value specialties such as Cardiology and
Neurosciences, leading to higher ARPOB
➢ Centre of Orthopedics & Spine &
▪ Organ transplant operations started in December 2022
Rheumatology ▪ Radiation oncology lines expected to be commissioned by January 2024, while
21 robotic surgeries expected to start in the coming quarter
 Payer mix
Balanced revenue split between payer categories

Self-payers FY2023
1,888
1,605
885

FY21 FY22 FY23

Self-payers Central, state

and others and local
Insurers through TPA 36% government
1,227 1,381 bodies
669 under
government
scheme
FY21 FY22 FY23 37%

Insurers acting through

third party
Government Bodies administrators
27%
1,934
1,177
733

FY21 FY22 FY23

22
Figures in Rs mn
 OUR
STRENGTHS

23
 Strengths

Among the leading

super-specialty hospital Regional advantage
in Delhi NCR

Advanced and high-end medical Experienced and professional

equipment and technology management team

Track record of stable

Team of highly qualified operating & financial
medical professionals performance

24
 Leading hospital in Delhi NCR, attracts patients from
adjoining states with inadequate healthcare facilities
2 of Yatharth’s hospitals are amongst top 10 largest private
Delhi NCR region hospitals in Delhi NCR*

Jhansi-Orchha- ➢ Noida, Greater Noida and Noida extension attract patients from the
Gwalior NCR region, other nearby states and even internationally

➢ Even with high bed densities, hospitals in the region have shown
high occupancy rates indicating potential for further growth and
expansion

➢ Opportunity to expand in other tier II cities of Northern India

➢ Diversified mix in terms of specialties, hospitals and customers

allows to maintain a relatively de-risked business proportions

Jhansi-
Greater Noida
Particulars Delhi-NCR Noida Ghaziabad Orchha-
Noida Extension
Gwalior

Population - 2021 ~70 million ~0.8 million ~0.8 million ~0.4 million ~6.5 million ~3.7 million

# Hospital beds ~163,000 ~4,300 ~2,500 ~1,000 ~7,200 ~7,900

25
*In terms of number of beds in FY2023 # Source: CRISIL
 Regional Advantage

Integrating talent from First mover advantage in

well-established allied building out network
workforce across Tier II/III cities

Promoters being
Stronger local connect doctors, have better
with people
26 connect with doctors
 Advanced and high-end medical equipment and technology

• Hospitals are equipped with machines and devices with sophisticated technology
• Strive to introduce cutting-edge medical technology and state-of-the-art equipment

• Catheterization Laboratory Diagnostic Certifications

• Computerized Tomography Scan
(CT Scan)
• Magnetic Resonance Imaging (MRI)
• State of the art imaging equipment
- Mammography, Advanced EEG,
Nerve conduction velocity,
Equipment • All hospitals are NABH accredited
• Received NABL certification for
Noida Extension hospital, and
Greater Noida hospital

+
advanced surgical equipment etc.

• Critical care units are equipped

• Well-equipped modular and other
operation theatres with three stage
air filtration and laminar flow
• Operating microscopes, image
intensifiers, and laparoscopic
equipment
with high-end patient monitoring
devices, ventilators and dedicated
isolation rooms
Operation • Facilities for haemodialysis,
Theatres Critical care sustained low-efficiency dialysis,
Equipment endoscopy and bronchoscopy are
available 24x7 by the bedside

27
 Team of highly qualified medical professionals
Number of Doctors (Sep’23) Full Time Employees (Sep’23)

Paramedical,
Nursing, 877 398

Visiting Specialist Resident

Doctors, 164 Doctors, 253 Medical
Resident Doctors, 224
Corporate and
Medical Support Staff, Specialist
Doctors, 224 1,823 Doctors, 253

Attrition to ease amidst strategic initiatives

8% Specialist
Doctors ❑ Introduced DNB program across 8 specialties in 2 of the hospitals
❑ DNB program to reduce attrition of Resident Medical Doctors
34% ❑ Total 24 resident doctors have joined the DNB program till date
Resident Medical
Doctors
43% ❑ Keep staff abreast with global developments concerning the
health sector
Other ❑ Provide better doctor visibility amongst the potential patients
Staff through marketing and awareness campaigns
28
 Experienced and professional management team

Leadership
Promoted by experienced medical
professionals, Dr. Ajay Kumar Tyagi and
Dr. Kapil Kumar Dr. Ajay Kumar Tyagi Dr. Kapil Kumar
Chairman & Whole-time Director Managing Director

Management
Led by experienced and qualified
professional management team

Yatharth Tyagi Amit Kumar Singh

Whole-time Director Chief Executive Officer
Brand
Strong brand equity led by
✓ First mover advantage in regional
territories
✓ One of the best healthcare infra
✓ Personalized connect with patients

29 Deepak Kumar Tyagi Pankaj Prabhakar

President, Strategy and Finance Chief Financial Officer
 Track record of stable operating and financial performance

Growth led by strong operational Optimizing Capex Allocation

1. Stable operating & efficiency: 1. Reinvesting in increasing bed
financial performance 1. Streamlining clinical and capacity and opening new hospitals
2. Continued growth over the past administrative functions 2. Incurring lower capital expenditure
three fiscals 2. Continually introducing process per operational bed
innovations 3. Making optimal use of the available
3. Maintaining economies of scale area in our hospitals and working
better with equipment suppliers

FY21-23 CAGR 5,203 3.91 3.72

FY23 (% of revenue) 27% 26%
Revenue: 51%
800 .00 4.0 0

4,009 3.07
EBITDA: 41% 21%
700 .00

18% 18% 17%

600 .00 3.0 0

500 .00

2,287
Rs mn

Rs mn
400 .00 2.0 0

1,108 1,338 300 .00

670 200 .00 1.0 0

337

409

432
100 .00

Material and Employee Cost EBITDA Margin

0.0 0 0.0 0

FY21 FY22 FY23 Consumables FY21 FY22 FY23

Revenue EBITDA Yatharth Peer Average Gross Capex Capex per Operational Bed
30
 Growth Strategy

Continue to Introduce new Grow medical Augment scale Further leverage

improve our specialties at tourism segment through organic technology to
quality of care existing hospitals to attract and inorganic grow operations
and operational international manner in current
efficiencies patients markets and
expand into
adjacent regions

31
 Key Growth Drivers (1/2)

Improving specialty mix Introduce new specialties at Grow medical tourism segment
towards high value specialties existing hospitals to attract international patients

➢ Increase in share of higher value ➢ Noida Extension taking the lead by ➢ Close proximity to the upcoming
specialties such as Neurology, offering radiation line for oncology Asia’s largest airport at Greater
Cardiology, Nephrology, treatments Noida
Orthopedics and Oncology,
resulting in higher ARPOB ➢ Kidney Transplant already started ➢ Focus on orthopedics, cardiac
at Noida Extension & Greater Noida, sciences, gastrointestinal surgery
➢ Further strengthening of super- and liver transplant to start soon and urology for international
specialties by on-boarding new patients
reputable and experienced doctors
➢ Align marketing strategies to target
➢ Incremental share of organ medical tourists
transplant in Greater Noida & Noida
Extension to enhance mix of high ➢ Started soft marketing of radiation
value specialties line

32
 Key Growth Drivers (2/2)

Leverage technology to grow Improving utilization & Jhansi

Targeting Balanced Growth
operations hospital stabilization

➢ Augment scale through organic ➢ Adopt the latest medical ➢ Focus towards increasing ARPOB
and inorganic manner in current technologies and equipment to and better management of ALOS in
markets and expand into adjacent improve the quality of care and Noida, Greater Noida & Noida
regions augment success rates of Extension
surgeries
➢ Expand in Tier II cities of Northern ➢ Jhansi operations began in FY23,
India ➢ Plan to introduce robotic surgeries with a utilization of 8%. With
stabilization of Jhansi hospital,
➢ Acquired adjacent land parcels in ARPOB & utilization to improve in
Greater Noida & Noida extension, to the coming quarters
support future growth opportunities

33
 Appendix

34
 Board of Directors (1/2)
Dr. Ajay Kumar Tyagi
Chairman & Whole-time Director
➢ Over 17 years of experience in medical
care and hospital management
➢ Associated with the Company since its
incorporation
➢ Previously associated with Medical
Health Family Welfare U.P. L.K.O
➢ Holds a degree of bachelor of medicine,
bachelor of surgery, and diploma in
orthopaedics
35
Dr. Kapil Kumar Yatharth Tyagi
Managing Director Whole-time Director
➢ Over 17 years of experience in medicine ➢ Associated with the company since 2019
and healthcare ➢ Holds a bachelor’s degree in business
➢ Associated with the Company since its and management from Leeds Beckett
incorporation University, United Kingdom and holds a
master of science degree in
➢ Previously associated with Lady Hardinge
International Health Management from
Medical College, Smt. Sucheta Kriplani
Imperial College, London
Hospital and Noida Orthopedic Hospital
➢ Responsible for overall operations and
➢ Holds a degree of bachelor of medicine,
business development for the company
bachelor of surgery, and master of
surgery in orthopedic surgery. Also
completed magister chirurgie in
orthopedics
 Board of Directors (2/2)
Promila Bhardwaj
Independent Director
➢ Over 35 years of experience in public
administration
➢ Joined Indian revenue services in the
year 1979, and retired as DGIT (Systems)
from Directorate of Income Tax
(systems)
➢ Holds a degree of bachelor of arts and
master’s of arts in English, master of
philosophy in social sciences, and
master’s diploma in public
administration
36
Mukesh Sharma
Independent Director
➢ Over 35 years of experience in banking
➢ Previously associated with Bank of
Baroda
➢ Holds a bachelor’s degree in science
agriculture & animal husbandry, master’s
degree in business administration and
post graduate diploma in labour law,
labour welfare and personnel
management, also holds a degree of
bachelor’s of law
Sanjeev Upadhyaya
Independent Director
➢ Over 20 years of experience in
community medicines
➢ Previously associated with E.S.I. Hospital,
Aga Khan Foundation Project, United
Nations’ Children’s Fund and other
organizations
➢ Holds a bachelor’s degree in medicine
and bachelor of surgery, and doctor of
medicine in community medicine
 Management Team
Amit Kumar Singh
Chief Executive Officer
➢ Over 17 years of experience in hospital
management
➢ Previously associated with Centre for
Sight, Raksha Medicare Private Limited,
Veeda Clinical Research Private Limited,
Indira Gandhi Eye Hospitals, Radiant Life
Care Private Limited
➢ Holds bachelor’s degree in art,
postgraduate diploma in Hospital and
Health Management
37
Pankaj Prabhakar
Chief Financial Officer
➢ Over 16 years of experience incorporate
finance of several healthcare institutions
➢ Previously associated with Rockland
Hospital, Max Devki Devi Heart & Vascular
Institute, Fortis Flt. L.T. Rajan Dhall
Hospital, Artemis Medicare Services
Private Limited, Max Healthcare Institute
Limited and Asian Institute of Medical
Sciences
➢ Holds a bachelor’s degree and is an
associate member of the Institute of
Chartered Accountants of India
Deepak Kumar Tyagi
President, Strategy and Finance
➢ Approximately 14 years of experience
incorporate finance
➢ Previously associated with Prometric
Testing Private Limited and Mind
Shapers Technologies Private Limited
➢ Holds a Bachelor’s degree in commerce
and completed course of study in French
from University of Delhi
➢ Associate member of the Institute of
Company Secretaries of India and the
Institute of Chartered Accountants of
India
 Shareholding Pattern

Shareholding Pattern*
BSE Ticker
543950

19.18% NSE Ticker

YATHARTH

5.42%

9.07% Market Capitalization*

66.33% Rs. 32,434 mn

No. of shares outstanding

8,58,50,233

Promoter Group DIIs FIIs Others

38
* As on September 30, 2023
 Thank You
www.yatharthhospitals.com

Yatharth Hospital & Trauma Care Services Ltd

CIN: L85110DL2008PLC174706
www.yatharthhospitals.com

Investor Relations
investor.relations@yatharthhospitals.com

39